Influenza Vaccine Market to grow by USD 2.56 Bn by 2026, Market Segmentation by Type and Geography - Technavio

NEW YORK, Oct. 19, 2022 /PRNewswire/ --The influenza vaccine market is set to grow by USD 2.56 billion, at a CAGR of 8.66% from 2021 to 2026. The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment.

Factors such as increasing prevalence and incidence of influenza, rising awareness about influenza vaccination, and initiation of immunization programs and research activities will offer immense growth opportunities.

To leverage the current opportunities, market vendors must strengthen their foothold in the fast-growing segments, while maintaining their positions in the slow-growing segments. The influenza vaccine market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Request Free Sample Report.

• Type 
• Live Attenuated Influenza Vaccines 
• The live attenuated influenza vaccines segment will significantly increase its market share. The amazing number of compounds undergoing Phase III clinical studies suggests that the market for live attenuated influenza vaccines will experience strong growth over the course of the projected period. The intensive R&D is anticipated to provide enhanced versions of current goods, which will boost the flu vaccine market.
• For the prevention of influenza, a number of authorized live attenuated influenza vaccinations are available. The upcoming products provide increased defense against more virus strains, resulting in better results. Recombinant influenza vaccines now account for a modest portion of the influenza vaccine industry worldwide. Due to the vaccine's production processes being independent of the availability of eggs, as opposed to other influenza vaccines that use a small amount of egg protein, this market niche is growing.
• Recombinant Influenza Vaccines
• Geography 
• North America
• North America will continue to dominate the global influenza vaccine market throughout the forecast period. The existence of governmental organizations like the Pan American Health Organization (PAHO), which offers suggested vaccination regimens, is vital in determining the regional market. Over the past few years, the prevalence of various infectious diseases, particularly influenza, has been rising significantly throughout the region's developed nations. Additionally, those applying for an immigrant visa in the US must comply with certain illness vaccine criteria. The World Health Organization (WHO) and CDC advise travelers entering the US to get immunized against diseases including influenza. Hence, the growing demand for influenza vaccination in countries across the region is expected to foster the growth of the influenza vaccine market in North America during the forecast period. 
• Europe
• Asia
• Rest Of World (ROW)

To know additional highlights and key points on various market segments and their impact in coming years, Buy Sample Report.

Global medical education is fragmented and the vendors are deploying various organic and inorganic growth strategies to compete in the market. 

Vendors are being driven by the intensifying market rivalry to implement a variety of growth methods, such as promotional efforts and spending on advertising, to increase the exposure of their services. In order to remain competitive in the market, several suppliers are also implementing inorganic expansion tactics like M&As.

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

• Altimmune Inc.
• AstraZeneca Plc
• Baxter International Inc.
• BioDiem
• BiondVax Pharmaceuticals Ltd.
• CSL Ltd.
• Emergent BioSolutions Inc.
• F. Hoffmann La Roche Ltd.
• FluGen Inc.
• GlaxoSmithKline Plc
• Medicago Inc
• Novavax Inc.

Find additional highlights on the growth strategies adopted by vendors and their product offerings, Download Free Sample Report. 

• CAGR of the market during the forecast period
• Detailed information on factors that will assist influenza vaccine market growth during the next five years
• Estimation of the influenza vaccine market size and its contribution to the parent market
• Predictions on upcoming trends and changes in consumer behavior
• The growth of the influenza vaccine market
• Analysis of the market's competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of influenza vaccine market vendors

Polycystic Kidney Disease Drugs Market by Type and Geography - Forecast and Analysis 2022-2026: The high prevalence of chronic kidney diseases is notably driving the polycystic kidney disease drugs market growth. The report extensively covers polycystic kidney disease drugs market segmentation by type (ADPKD and ARPKD) and geography (North America, Europe, Asia, and Rest of World (ROW)).

Mono Vaccine Market by Type and Geography - Forecast and Analysis 2022-2026: The increase in the pediatric population is one of the key factors driving the global mono vaccine market growth. The report extensively covers the mono vaccine market segmentation by type (meningococcal vaccine, Japanese encephalitis vaccine, hepatitis vaccine, yellow fever vaccine, and others) and geography (North America, Europe, Asia, and the Rest of the World (ROW)). 

1 Executive Summary

• 1.1 Market Overview 
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
• Exhibit 06: Executive Summary – Chart on Incremental Growth
• Exhibit 07: Executive Summary – Data Table on Incremental Growth
• Exhibit 08: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem 
• Exhibit 09: Parent market
• Exhibit 10: Market Characteristics

3 Market Sizing

• 3.1 Market definition 
• Exhibit 11: Offerings of vendors included in the market definition

• 3.2 Market segment analysis 
• Exhibit 12: Market segments

• 3.3 Market size 2021

• 3.4 Market outlook: Forecast for 2021-2026 
• Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
• Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
• Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)

4 Five Forces Analysis

• 4.1 Five forces summary 
• Exhibit 17: Five forces analysis - Comparison between2021 and 2026

• 4.2 Bargaining power of buyers 
• Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026

• 4.3 Bargaining power of suppliers 
• Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026

• 4.4 Threat of new entrants 
• Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026

• 4.5 Threat of substitutes 
• Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026

• 4.6 Threat of rivalry 
• Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026

• 4.7 Market condition 
• Exhibit 23: Chart on Market condition - Five forces 2021 and 2026

5 Market Segmentation by Type

• 5.1 Market segments 
• Exhibit 24: Chart on Type - Market share 2021-2026 (%)
• Exhibit 25: Data Table on Type - Market share 2021-2026 (%)

• 5.2 Comparison by Type 
• Exhibit 26: Chart on Comparison by Type
• Exhibit 27: Data Table on Comparison by Type

• 5.3 Live attenuated influenza vaccines - Market size and forecast 2021-2026 
• Exhibit 28: Chart on Live attenuated influenza vaccines - Market size and forecast 2021-2026 ($ million)
• Exhibit 29: Data Table on Live attenuated influenza vaccines - Market size and forecast 2021-2026 ($ million)
• Exhibit 30: Chart on Live attenuated influenza vaccines - Year-over-year growth 2021-2026 (%)
• Exhibit 31: Data Table on Live attenuated influenza vaccines - Year-over-year growth 2021-2026 (%)

• 5.4 Recombinant influenza vaccines - Market size and forecast 2021-2026 
• Exhibit 32: Chart on Recombinant influenza vaccines - Market size and forecast 2021-2026 ($ million)
• Exhibit 33: Data Table on Recombinant influenza vaccines - Market size and forecast 2021-2026 ($ million)
• Exhibit 34: Chart on Recombinant influenza vaccines - Year-over-year growth 2021-2026 (%)
• Exhibit 35: Data Table on Recombinant influenza vaccines - Year-over-year growth 2021-2026 (%)

• 5.5 Market opportunity by Type 
• Exhibit 36: Market opportunity by Type ($ million)

6 Customer Landscape

• 6.1 Customer landscape overview 
• Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

7 Geographic Landscape

• 7.1 Geographic segmentation 
• Exhibit 38: Chart on Market share by geography 2021-2026 (%)
• Exhibit 39: Data Table on Market share by geography 2021-2026 (%)

• 7.2 Geographic comparison 
• Exhibit 40: Chart on Geographic comparison
• Exhibit 41: Data Table on Geographic comparison

• 7.3 North America - Market size and forecast 2021-2026
• Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million)
• Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%)
• Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%)

• 7.4 Europe - Market size and forecast 2021-2026
• Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
• Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%)
• Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%)

• 7.5 Asia - Market size and forecast 2021-2026
• Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
• Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%)
• Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%)

• 7.6 Rest of World (ROW) - Market size and forecast 2021-2026
• Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
• Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
• Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)

• 7.7 US - Market size and forecast 2021-2026
• Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million)
• Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%)
• Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%)

• 7.8 UK - Market size and forecast 2021-2026
• Exhibit 62: Chart on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 63: Data Table on UK - Market size and forecast 2021-2026 ($ million)
• Exhibit 64: Chart on UK - Year-over-year growth 2021-2026 (%)
• Exhibit 65: Data Table on UK - Year-over-year growth 2021-2026 (%)

• 7.9 China - Market size and forecast 2021-2026
• Exhibit 66: Chart on China - Market size and forecast 2021-2026 ($ million)
• Exhibit 67: Data Table on China - Market size and forecast 2021-2026 ($ million)
• Exhibit 68: Chart on China - Year-over-year growth 2021-2026 (%)
• Exhibit 69: Data Table on China - Year-over-year growth 2021-2026 (%)

• 7.10 Canada - Market size and forecast 2021-2026
• Exhibit 70: Chart on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 71: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
• Exhibit 72: Chart on Canada - Year-over-year growth 2021-2026 (%)
• Exhibit 73: Data Table on Canada - Year-over-year growth 2021-2026 (%)

• 7.11 India - Market size and forecast 2021-2026
• Exhibit 74: Chart on India - Market size and forecast 2021-2026 ($ million)
• Exhibit 75: Data Table on India - Market size and forecast 2021-2026 ($ million)
• Exhibit 76: Chart on India - Year-over-year growth 2021-2026 (%)
• Exhibit 77: Data Table on India - Year-over-year growth 2021-2026 (%)

• 7.12 Market opportunity by geography 
• Exhibit 78: Market opportunity by geography ($ million)

8 Drivers, Challenges, and Trends

• 8.1 Market drivers

• 8.2 Market challenges

• 8.3 Impact of drivers and challenges 
• Exhibit 79: Impact of drivers and challenges in 2021 and 2026

• 8.4 Market trends

9 Vendor Landscape

• 9.1 Overview

• 9.2 Vendor landscape 
• Exhibit 80: Overview on Criticality of inputs and Factors of differentiation

• 9.3 Landscape disruption 
• Exhibit 81: Overview on factors of disruption

• 9.4 Industry risks 
• Exhibit 82: Impact of key risks on business

10 Vendor Analysis

• 10.1 Vendors covered 
• Exhibit 83: Vendors covered

• 10.2 Market positioning of vendors 
• Exhibit 84: Matrix on vendor position and classification

• 10.3 Altimmune Inc. 
• Exhibit 85: Altimmune Inc. - Overview
• Exhibit 86: Altimmune Inc. - Business segments
• Exhibit 87: Altimmune Inc. - Key news
• Exhibit 88: Altimmune Inc. - Key offerings
• Exhibit 89: Altimmune Inc. - Segment focus

• 10.4 AstraZeneca Plc 
• Exhibit 90: AstraZeneca Plc - Overview
• Exhibit 91: AstraZeneca Plc - Product / Service
• Exhibit 92: AstraZeneca Plc - Key news
• Exhibit 93: AstraZeneca Plc - Key offerings

• 10.5 Baxter International Inc. 
• Exhibit 94: Baxter International Inc. - Overview
• Exhibit 95: Baxter International Inc. - Business segments
• Exhibit 96: Baxter International Inc. - Key news
• Exhibit 97: Baxter International Inc. - Key offerings
• Exhibit 98: Baxter International Inc. - Segment focus

• 10.6 BiondVax Pharmaceuticals Ltd. 
• Exhibit 99: BiondVax Pharmaceuticals Ltd. - Overview
• Exhibit 100: BiondVax Pharmaceuticals Ltd. - Product / Service
• Exhibit 101: BiondVax Pharmaceuticals Ltd. - Key offerings

• 10.7 CSL Ltd. 
• Exhibit 102: CSL Ltd. - Overview
• Exhibit 103: CSL Ltd. - Business segments
• Exhibit 104: CSL Ltd. - Key news
• Exhibit 105: CSL Ltd. - Key offerings
• Exhibit 106: CSL Ltd. - Segment focus

• 10.8 FluGen Inc. 
• Exhibit 107: FluGen Inc. - Overview
• Exhibit 108: FluGen Inc. - Product / Service
• Exhibit 109: FluGen Inc. - Key offerings

• 10.9 GlaxoSmithKline Plc 
• Exhibit 110: GlaxoSmithKline Plc - Overview
• Exhibit 111: GlaxoSmithKline Plc - Business segments
• Exhibit 112: GlaxoSmithKline Plc - Key news
• Exhibit 113: GlaxoSmithKline Plc - Key offerings
• Exhibit 114: GlaxoSmithKline Plc - Segment focus

• 10.10 Medicago Inc 
• Exhibit 115: Medicago Inc - Overview
• Exhibit 116: Medicago Inc - Product / Service
• Exhibit 117: Medicago Inc - Key offerings

• 10.11 Novavax Inc. 
• Exhibit 118: Novavax Inc. - Overview
• Exhibit 119: Novavax Inc. - Product / Service
• Exhibit 120: Novavax Inc. - Key offerings

• 10.12 Sanofi 
• Exhibit 121: Sanofi - Overview
• Exhibit 122: Sanofi - Business segments
• Exhibit 123: Sanofi - Key news
• Exhibit 124: Sanofi - Key offerings
• Exhibit 125: Sanofi - Segment focus

11 Appendix

• 11.1 Scope of the report

• 11.2 Inclusions and exclusions checklist 
• Exhibit 126: Inclusions checklist
• Exhibit 127: Exclusions checklist

• 11.3 Currency conversion rates for US$ 
• Exhibit 128: Currency conversion rates for US$

• 11.4 Research methodology 
• Exhibit 129: Research methodology
• Exhibit 130: Validation techniques employed for market sizing
• Exhibit 131: Information sources

• 11.5 List of abbreviations 
• Exhibit 132: List of abbreviations

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED